Wasatch Core Growth Fund’s underperformance was largely due to one factor—lack of exposure to biotechnology stocks. Read more here.
RBC said that shares of Palantir are still trading at an "unfavorable" risk-reward ratio, despite shedding 9% over the past ...
Jan 27 (Reuters) - British bootmaker Dr ‌Martens ​posted a decline in ‌quarterly sales and forecast broadly flat annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results